Lucid Diligence Brief: Triana Biomedicines $120M Series B for TRI-611 in ALK+ NSCLC
Lucid Diligence Brief: Triana Biomedicines $120M Series B for TRI-611 in ALK+…
Lucid Diligence Brief: Paradigm to acquire Flatiron’s Clinical Research Business
Lucid Diligence Brief: Paradigm to acquire Flatiron’s Clinical Research…
Lucid Diligence Brief: CorriXR × InhaTarget × Merxin, inhaled CRISPR therapy for lung cancer
Lucid Diligence Brief: CorriXR × InhaTarget × Merxin, inhaled CRISPR therapy…
Lucid Diligence Brief: Circular Genomics $15 million Series A for circular RNA biomarkers
Lucid Diligence Brief: Circular Genomics $15 million Series A for circular RNA…
Lucid Diligence Brief: Regeneron and Tessera team on TSRA-196 for AATD
Lucid Diligence Brief: Regeneron and Tessera team on TSRA-196 for AATD…
Lucid Diligence Brief: Protego Biopharma $130M Series B
Lucid Diligence Brief: Protego Biopharma $130M Series B Professional audiences…
Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer
Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer…
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration Professional…
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+ Professional audiences…
Lucid Diligence Brief: Made Scientific and Cellergy Therapeutics manufacturing partnership to advance CLG-001
Lucid Diligence Brief: Made Scientific and Cellergy Therapeutics manufacturing…
Lucid Diligence Brief: Sprint Bioscience sells TREX1 program to Gilead
Lucid Diligence Brief: Sprint Bioscience sells TREX1 program to Gilead…
Lucid Diligence Brief: Vaximm VXM01 License Term Sheet with BCM Europe
Lucid Diligence Brief: Vaximm VXM01 License Term Sheet with BCM Europe…